Amgen

Incorporated in 1980, the company has its headquarters based in Thousand Oaks, California, United States. It operates in several key business categories including Oncology/Hematology, Cardiovascular, Inflammation, Bone Health, Neuroscience, and Nephrology, along with other products. The firm has developed and marketed a variety of major brands, with some of its most notable being Enbrel (etanercept), Neulasta (pegfilgrastim), Prolia (denosumab), Xgeva (denosumab), Aranesp (darbepoetin alfa), Otezla (apremilast), Kyprolis (carfilzomib), Repatha (evolocumab), and Aimovig (erenumab-aooe). These products have a strong market presence globally, with significant sales in the United States, Europe, Canada, and Japan. In addition to these major markets, the company's products are available in various countries across the world, albeit on a smaller scale. (Powered by AI)